Practitioner's Docket No. 1392/10/19 PCT/US
U.S. Serial No. 10/533,232

CHAPTER II

IN THE UNITED STATES ELECTED OFFICE (EO/US)

PCT/US03/41200	23 December 2003 (23.12.03)	26 December 2002 (26.12.02)
International Application No.	International Filing Date	Priority Date Claimed

CELL PROLIFERATION-RELATED POLYPEPTIDES AND USES THEREFOR

Title of Invention

Syngenta Participations AG; Cooper, Bret

Applicant(s)

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
 ATTENTION: EO/US

COMPLETION OF FILING REQUIREMENTS
FOR INTERNATIONAL APPLICATION ENTERING U.S. NATIONAL STAGE
IN U.S. ELECTED OFFICE (EO/US) UNDER 35 U.S.C. § 371

This replies to the Notice of Missing Requirements under 35 U.S.C. § 371 and 37 C.F.R. § 1.495 (FORM PCT/DO/EO/905).
A copy of FORM PCT/DO/EO/905 accompanies this response.

EXPRESS MAILING UNDER 37 C.F.R. § 1.10*
(Express Mail label number is mandatory.)
(Express Mail certification is optional)

I hereby certify that this paper, along with any document referred to, is being deposited with the United States Postal Service on this date
___November 22, 2005___ in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 as "Express Mail Post Office to Addressee" Mailing Label No. ___EV579134359US___ .

Stacie H. Boswell

Date: _November 22, 2005_

Signature of person certifying

WARNING: Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care. requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439. at 56,442.

DECLARATION OR OATH

I. The declaration or oath that was filed was determined to be defective. A new original oath or declaration is attached.

SEQUENCE LISTING

II. The computer readable form of the Sequence Listing that was filed with the subject application has been found not to comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821-1.825. A substitute computer readable form, a Substitute Sequence Listing on CD-R (in triplicate), a Statement Regarding Identity of Copies of Sequence Listing, and a Preliminary Amendment directing entry of the Substitute Sequence Listing into the application are enclosed herewith.

III.   **FEES**

1. Surcharge fees
   Surcharge for filing the oath or declaration
   later than thirty months from the priority
   date pursuant to § 1.495(c): $130.00
                                    Total Fees   **$130.00**

EXTENSION OF TIME

IV. The proceedings herein are for a patent application. Accordingly, the provisions of 37 C.F.R. § 1.136(a) apply.

Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

TOTAL FEE DUE

V. The total fee due is:
   Completion fee(s) $130.00
                                    TOTAL FEE DUE $130.00

PAYMENT OF FEES

VI.

Authorization is hereby made to charge the amount of $130.00 to Deposit Account No. 50-0426. Charge any additional fees required by this paper or credit any overpayment in the manner authorized above.
A duplicate of this request is attached.

Date: 11/22/2005

Reg. No.: 39,395
Tel. No.: 001-919-493-8000
Customer No.: 25297

11/29/2005 ATRAN1   00000110 500426   10533232

01 FC:1617   130.00 DA

Signature of Practitioner
Arles A. Taylor, Jr.
Jenkins, Wilson & Taylor, P.A.
Suite 1400 University Tower
3100 Tower Boulevard
Durham, NC 27707
UNITED STATES OF AMERICA

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/533,232	Bret Cooper	1392/10/19 PCT/US

INTERNATIONAL APPLICATION NO.		
PCT/US03/41200		
I.A. FILING DATE	PRIORITY DATE	
12/23/2003	12/26/2002	

25297
JENKINS, WILSON & TAYLOR, P. A.
3100 TOWER BLVD
SUITE 1400
DURHAM, NC 27707

**CONFIRMATION NO. 2354**

371 FORMALITIES LETTER

OC000000017076491

Date Mailed: 09/23/2005

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 04/29/2005
- Biochemical Sequence Diskette filed on 04/29/2005
- Oath or Declaration filed on 04/29/2005
- U.S. Basic National Fees filed on 04/29/2005
- Priority Documents filed on 04/29/2005
- Specification filed on 04/29/2005
- Claims filed on 04/29/2005
- Abstracts filed on 04/29/2005
- Drawings filed on 04/29/2005

RECEIVED
SEP 29 2005

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
    - is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68.

- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of $130 for a non-small entity, must be submitted with the missing items identified in this letter.

SUMMARY OF FEES DUE:

DOCKET DATES: 2|23· 3|27|06
ASSIGNED ATTY: AAT CPP
FILE NO. 1392|10|19 PCT|I
DOCKETED BY: HMD
DATE: 10·19·05

Total additional fees required for this application is **$130** for a Large Entity:

- **$130** Surcharge.

  - This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application** and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
  - A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- **For Rules Interpretation, call (571) 272-0951**
- **For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- **Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov**

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/533,232	PCT/US03/41200	1392/10/19 PCT/US

FORM PCT/DO/EO/905 (371 Formalities Notice)

RAW SEQUENCE LISTING
ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: _10/533232_

Source: _PG_

Date Processed by STIC: _5/12/5_

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:
1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER VERSION 4.2 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.
Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.
Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm> , **EFS Submission User Manual** - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 06/05/04):
U.S. Patent and Trademark Office, 220 20th Street S., Customer Window, Mail Stop Sequence, Crystal Plaza Two, Lobby, Room 1B03, Arlington, VA 22202

Revised 05/17/04

ERROR DETECTED   **SUGGESTED CORRECTION**   SERIAL NUMBER: 10/533,232

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

1 ____ Wrapped Nucleics / Wrapped Aminos — The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .); this will prevent "wrapping."

2 ____ Invalid Line Length — The rules require that a line not exceed 72 characters in length. This includes white spaces.

3 ____ Misaligned Amino Numbering — The numbering under each 5ᵗʰ amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.

4 ____ Non-ASCII — The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.

5 ____ Variable Length — Sequence(s) ____ contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing

6 ____ PatentIn 2.0 "bug" — A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) ____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.

7 ____ Skipped Sequences (OLD RULES) — Sequence(s) ____ missing. If intentional, please insert the following lines for each skipped sequence
(2) INFORMATION FOR SEQ ID NO X (insert SEQ ID NO where "X" is shown)
(i)   SEQUENCE CHARACTERISTICS (Do not insert any subheadings under this heading)
(xi) SEQUENCE DESCRIPTION SEQ ID NO X (insert SEQ ID NO where "X" is shown)
This sequence is intentionally skipped

Please also adjust the "(ii) NUMBER OF SEQUENCES" response to include the skipped sequences.

8 ____ Skipped Sequences (NEW RULES) — Sequence(s) ____ missing. If intentional, please insert the following lines for each skipped sequence
<210> sequence id number
<400> sequence id number
000

9 ____ Use of n's or Xaa's (NEW RULES) — Use of n's and/or Xaa's have been detected in the Sequence Listing.
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents

10 ____ Invalid <213> Response — Per 1.823 of Sequence Rules, the only valid <213> responses are Unknown, Artificial Sequence or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence

11 ____ Use of <220> — Sequence(s) ____ missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 07/01/1998, Vol. 63, No. 104, pp. 29631-32)   (Sec. 1.823 of Sequence Rules)

12 ____ PatentIn 2.0 "bug" — Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.

13 ____ Misuse of n/Xaa — "n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid

PCT

RAW SEQUENCE LISTING   DATE: 05/12/2005
PATENT APPLICATION: US/10/533,232   TIME: 08:24:04

Input Set : D:\1392-10-19 PCT.ST25.txt
Output Set: N:\CRF4\05122005\J533232.raw

```
 3 <110> APPLICANT: Cooper, Bret
 5 <120> TITLE OF INVENTION: CELL PROLIFERATION-RELATED POLYPEPTIDES AND USES THEREFOR
 7 <130> FILE REFERENCE: 1392-10-19-2
 9 <140> CURRENT APPLICATION NUMBER: US/10/533,232
 9 <141> CURRENT FILING DATE: 2005-04-29
 9 <150> PRIOR APPLICATION NUMBER: US 60/436,565
10 <151> PRIOR FILING DATE: 2002-12-26
12 <160> NUMBER OF SEQ ID NOS: 349
14 <170> SOFTWARE: PatentIn version 3.2
16 <210> SEQ ID NO: 1
17 <211> LENGTH: 885
18 <212> TYPE: DNA
19 <213> ORGANISM: Oryza sativa
22 <220> FEATURE:
23 <221> NAME/KEY: CDS
24 <222> LOCATION: (1)..(885)
26 <400> SEQUENCE: 1
27 atg gcg cct ccc tgc ggc gat gcc gcg gcg gct gcc tcc gcc gcg ccc    48
28 Met Ala Pro Pro Cys Gly Asp Ala Ala Ala Ala Ala Ser Ala Ala Pro
29 1               5                   10                  15
31 ggc ctg gcc aac ctg ctc att cgc gaa ggc gcc ggc ctc cct tcg cgt    96
32 Gly Leu Ala Asn Leu Leu Ile Arg Glu Gly Ala Gly Leu Pro Ser Arg
33                 20                  25                  30
35 ccc gaa cgg tac ccg cca ttc cgg ccc tgt act tct gat tcc ttt gct   144
36 Pro Glu Arg Tyr Pro Pro Phe Arg Pro Cys Thr Ser Asp Ser Phe Ala
37             35                  40                  45
39 cca atc tct agg gaa ggg gac gat att ccc ccc caa aaa aaa tcg gtt   192
40 Pro Ile Ser Arg Glu Gly Asp Asp Ile Pro Pro Gln Lys Lys Ser Val
41     50                  55                  60
43 tct tta cgc agc ggc ggc ggc ggc aat gcg gca gag agg gag gag ggc   240
44 Ser Leu Arg Ser Gly Gly Gly Gly Asn Ala Ala Glu Arg Glu Glu Gly
45 65                  70                  75                  80
47 ggt gcg aac agg aac ggg aag aag gag aag acc ggg gcg cag agg atc   288
48 Gly Ala Asn Arg Asn Gly Lys Lys Glu Lys Thr Gly Ala Gln Arg Ile
49                 85                  90                  95
51 acc ggg tgg ggg ctc cgt gag ttc agc aag ata gtt tct aag aaa gtt   336
52 Thr Gly Trp Gly Leu Arg Glu Phe Ser Lys Ile Val Ser Lys Lys Val
53                 100                 105                 110
55 gag gcc aaa gga aga acc aca tat aat gag gtt gcc gat gag att ttt   384
56 Glu Ala Lys Gly Arg Thr Thr Tyr Asn Glu Val Ala Asp Glu Ile Phe
57             115                 120                 125
59 gcg gag ctg aag tcc att acg cag aac ggt ctg gag ttt gat gag aag   432
60 Ala Glu Leu Lys Ser Ile Thr Gln Asn Gly Leu Glu Phe Asp Glu Lys
```

```
61       130                   135                   140
63 aat att agg cgg agg gta tat gat gct ttc aat gtg ctc att gca att      480
64 Asn Ile Arg Arg Arg Val Tyr Asp Ala Phe Asn Val Leu Ile Ala Ile
65 145                   150                   155                   160
67 cgt gtt att gca aaa gat aaa aag gag ata aag tgg atg ggc ctt act      528
68 Arg Val Ile Ala Lys Asp Lys Lys Glu Ile Lys Trp Met Gly Leu Thr
69                   165                   170                   175
71 aat tat aga tac gaa aag ata cag aag ttg gag gaa gtt cac aaa gaa      576
72 Asn Tyr Arg Tyr Glu Lys Ile Gln Lys Leu Glu Glu Val His Lys Glu
73          180                   185                   190
75 ctc atc acc agg atc aag aat aag aag aag ctt ctc cag gaa att gaa      624
76 Leu Ile Thr Arg Ile Lys Asn Lys Lys Lys Leu Leu Gln Glu Ile Glu
77          195                   200                   205
79 aag cag ttt gat gac ctt cag aat att aca tta cgc aac cag gct agt      672
80 Lys Gln Phe Asp Asp Leu Gln Asn Ile Thr Leu Arg Asn Gln Ala Ser
81       210                   215                   220
83 cag agg cca gca gaa agt gtt aat ggc atc ctc ctt ccg ttc tta ttg      720
84 Gln Arg Pro Ala Glu Ser Val Asn Gly Ile Leu Leu Pro Phe Leu Leu
85 225                   230                   235                   240
87 atc aag aca tcc cga aaa gca agg gtg gaa att gag att tcg gaa gat      768
88 Ile Lys Thr Ser Arg Lys Ala Arg Val Glu Ile Glu Ile Ser Glu Asp
89                   245                   250                   255
91 tcg aag ttt gca cgg ttc gac ttc aac ggt gca cca ttc acc atg cat      816
92 Ser Lys Phe Ala Arg Phe Asp Phe Asn Gly Ala Pro Phe Thr Met His
93          260                   265                   270
95 gat gat gta tca atc ctt gaa gcc atc agg cgt aac aaa gga aga gct      864
96 Asp Asp Val Ser Ile Leu Glu Ala Ile Arg Arg Asn Lys Gly Arg Ala
97          275                   280                   285
99 ggc ctc tcc att cac cct taa                                         885
100 Gly Leu Ser Ile His Pro
101      290
104 <210> SEQ ID NO: 2
105 <211> LENGTH: 294
106 <212> TYPE: PRT
107 <213> ORGANISM: Oryza sativa
109 <400> SEQUENCE: 2
111 Met Ala Pro Pro Cys Gly Asp Ala Ala Ala Ala Ala Ser Ala Ala Pro
112 1               5                   10                  15
115 Gly Leu Ala Asn Leu Leu Ile Arg Glu Gly Ala Gly Leu Pro Ser Arg
116             20                  25                  30
119 Pro Glu Arg Tyr Pro Pro Phe Arg Pro Cys Thr Ser Asp Ser Phe Ala
120         35                  40                  45
123 Pro Ile Ser Arg Glu Gly Asp Asp Ile Pro Pro Gln Lys Lys Ser Val
124     50                  55                  60
127 Ser Leu Arg Ser Gly Gly Gly Gly Asn Ala Ala Glu Arg Glu Glu Gly
128 65                  70                  75                  80
131 Gly Ala Asn Arg Asn Gly Lys Lys Glu Lys Thr Gly Ala Gln Arg Ile
132             85                  90                  95
135 Thr Gly Trp Gly Leu Arg Glu Phe Ser Lys Ile Val Ser Lys Lys Val
```

RAW SEQUENCE LISTING　　　　　　　DATE: 05/12/2005
PATENT APPLICATION:　US/10/533,232　　　TIME: 08:24:04

Input Set : D:\1392-10-19 PCT.ST25.txt
Output Set: N:\CRF4\05122005\J533232.raw

```
136                    100              105                  110
139 Glu Ala Lys Gly Arg Thr Thr Tyr Asn Glu Val Ala Asp Glu Ile Phe
140        115             120                 125
143 Ala Glu Leu Lys Ser Ile Thr Gln Asn Gly Leu Glu Phe Asp Glu Lys
144    130                 135                 140
147 Asn Ile Arg Arg Arg Val Tyr Asp Ala Phe Asn Val Leu Ile Ala Ile
148 145                 150                 155                 160
151 Arg Val Ile Ala Lys Asp Lys Lys Glu Ile Lys Trp Met Gly Leu Thr
152                 165                 170                 175
155 Asn Tyr Arg Tyr Glu Lys Ile Gln Lys Leu Glu Glu Val His Lys Glu
156                 180                 185                 190
159 Leu Ile Thr Arg Ile Lys Asn Lys Lys Lys Leu Leu Gln Glu Ile Glu
160                 195             200                 205
163 Lys Gln Phe Asp Asp Leu Gln Asn Ile Thr Leu Arg Asn Gln Ala Ser
164    210                 215                 220
167 Gln Arg Pro Ala Glu Ser Val Asn Gly Ile Leu Leu Pro Phe Leu Leu
168 225                 230                 235                 240
171 Ile Lys Thr Ser Arg Lys Ala Arg Val Glu Ile Glu Ile Ser Glu Asp
172                 245                 250                 255
175 Ser Lys Phe Ala Arg Phe Asp Phe Asn Gly Ala Pro Phe Thr Met His
176                 260                 265                 270
179 Asp Asp Val Ser Ile Leu Glu Ala Ile Arg Arg Asn Lys Gly Arg Ala
180                 275             280                 285
183 Gly Leu Ser Ile His Pro
184        290
187 <210> SEQ ID NO: 3
188 <211> LENGTH: 1041
189 <212> TYPE: DNA
190 <213> ORGANISM: Oryza sativa
193 <220> FEATURE:
194 <221> NAME/KEY: CDS
195 <222> LOCATION: (1)..(1041)
197 <400> SEQUENCE: 3
198 atg gtc tcc ggc gcg gcg cat tcg gcc tcc acc agt ggc ggc ggc ggg      48
199 Met Val Ser Gly Ala Ala His Ser Ala Ser Thr Ser Gly Gly Gly Gly
200 1               5                   10                  15
202 ggg agc gag ggc tcc ccc acc ggc cgc gcc gcg ccg ggc atg cag ggc      96
203 Gly Ser Glu Gly Ser Pro Thr Gly Arg Ala Ala Pro Gly Met Gln Gly
204                 20                  25                  30
206 ggc ggc agc gcc gcc acg ccc gcc gcc tcg gcc tcc gcg tcc acg ccg     144
207 Gly Gly Ser Ala Ala Thr Pro Ala Ala Ser Ala Ser Ala Ser Thr Pro
208    35                  40                  45
210 gcc agc gag acc acc gtc gcc cgc cgc ctc gac ggc ctc gac atc cag     192
211 Ala Ser Glu Thr Thr Val Ala Arg Arg Leu Asp Gly Leu Asp Ile Gln
212    50                  55                  60
214 ggc gac gac gcg ccc tcg tcg cag ccc gcc acg agc aag aag aaa aaa     240
215 Gly Asp Asp Ala Pro Ser Ser Gln Pro Ala Thr Ser Lys Lys Lys Lys
216 65                  70                  75                  80
218 agg ggg cct gga aca cgt gca acg ggc cct gac aag ggt ggc cgt gga     288
```

```
219 Arg Gly Pro Gly Thr Arg Ala Thr Gly Pro Asp Lys Gly Gly Arg Gly
220             85              90              95
222 ttg cgc caa ttt agt atg aaa gtt tgt gag aaa gtt gaa agc aaa ggg    336
223 Leu Arg Gln Phe Ser Met Lys Val Cys Glu Lys Val Glu Ser Lys Gly
224             100             105             110
226 aga aca acc tac aac gag gtg gca gat gag ctt gta gct gag ttt gca    384
227 Arg Thr Thr Tyr Asn Glu Val Ala Asp Glu Leu Val Ala Glu Phe Ala
228             115             120             125
230 gac ccc aac aat aat ttt gca tca cct gat cct gac aac cct aac aca    432
231 Asp Pro Asn Asn Asn Phe Ala Ser Pro Asp Pro Asp Asn Pro Asn Thr
232         130             135             140
234 cca caa ttt gat gag aaa aat ata cga cga agg gtt tat gat gca ttg    480
235 Pro Gln Phe Asp Glu Lys Asn Ile Arg Arg Arg Val Tyr Asp Ala Leu
236 145             150             155             160
238 aat gtc ctg atg gct atg gat att ata tct aag gat aaa aag gaa att    528
239 Asn Val Leu Met Ala Met Asp Ile Ile Ser Lys Asp Lys Lys Glu Ile
240             165             170             175
242 cag tgg aag ggc ttg cct cgg aca agt atg agc gat gtt gaa gaa ttg    576
243 Gln Trp Lys Gly Leu Pro Arg Thr Ser Met Ser Asp Val Glu Glu Leu
244             180             185             190
246 aag aca gag atc atc gga ctg aaa ggt agg atc gac aag aaa aat gca    624
247 Lys Thr Glu Ile Ile Gly Leu Lys Gly Arg Ile Asp Lys Lys Asn Ala
248             195             200             205
250 tat ttg cag gag tta gaa gat caa ttt gta ggt ctt caa aac ttg gca    672
251 Tyr Leu Gln Glu Leu Glu Asp Gln Phe Val Gly Leu Gln Asn Leu Ala
252 210             215             220
254 cag cga aac gag cag ctt tat ggt tca gga aat gct cct tca gga gga    720
255 Gln Arg Asn Glu Gln Leu Tyr Gly Ser Gly Asn Ala Pro Ser Gly Gly
256 225             230             235             240
258 gtg gca ttg cca ttt ata ttg gtg cag aca cgt cct cat gct aca gta    768
259 Val Ala Leu Pro Phe Ile Leu Val Gln Thr Arg Pro His Ala Thr Val
260             245             250             255
262 gaa gtg gag ata tca gaa gat atg cag ctg gtg cat ttt gat ttc aat    816
263 Glu Val Glu Ile Ser Glu Asp Met Gln Leu Val His Phe Asp Phe Asn
264             260             265             270
266 agc act cca ttt gaa ctg cat gac gat tcc ttt gta ctg aaa gca ttg    864
267 Ser Thr Pro Phe Glu Leu His Asp Asp Ser Phe Val Leu Lys Ala Leu
268         275             280             285
270 ggg ttc tct ggc aaa gaa cca gat gat acg caa gcc tgg gtt gga aat    912
271 Gly Phe Ser Gly Lys Glu Pro Asp Asp Thr Gln Ala Trp Val Gly Asn
272     290             295             300
274 gga ggt gag tgc tca acc aca cct atc tat cat caa tca ccc caa gtt    960
275 Gly Gly Glu Cys Ser Thr Thr Pro Ile Tyr His Gln Ser Pro Gln Val
276 305             310             315             320
278 gcg agg cca aac gga gtt aga cta cca aca tcg ccc cct att ccc ggt    1008
279 Ala Arg Pro Asn Gly Val Arg Leu Pro Thr Ser Pro Pro Ile Pro Gly
280             325             330             335
282 ata ctt aaa ggg cgt gtc aag cat gaa cat tag    1041
283 Ile Leu Lys Gly Arg Val Lys His Glu His
```

Input Set : D:\1392-10-19 PCT.ST25.txt
Output Set: N:\CRF4\05122005\J533232.raw

```
284              340                 345
287 <210> SEQ ID NO: 4
288 <211> LENGTH: 346
289 <212> TYPE: PRT
290 <213> ORGANISM: Oryza sativa
292 <400> SEQUENCE: 4
294 Met Val Ser Gly Ala Ala His Ser Ala Ser Thr Ser Gly Gly Gly Gly
295 1               5                10                  15
298 Gly Ser Glu Gly Ser Pro Thr Gly Arg Ala Ala Pro Gly Met Gln Gly
299             20                  25                  30
302 Gly Gly Ser Ala Ala Thr Pro Ala Ala Ser Ala Ser Ala Ser Thr Pro
303             35                  40                  45
306 Ala Ser Glu Thr Thr Val Ala Arg Arg Leu Asp Gly Leu Asp Ile Gln
307         50                  55                  60
310 Gly Asp Asp Ala Pro Ser Ser Gln Pro Ala Thr Ser Lys Lys Lys Lys
311 65                  70                  75                  80
314 Arg Gly Pro Gly Thr Arg Ala Thr Gly Pro Asp Lys Gly Gly Arg Gly
315                 85                  90                  95
318 Leu Arg Gln Phe Ser Met Lys Val Cys Glu Lys Val Glu Ser Lys Gly
319             100                 105                 110
322 Arg Thr Thr Tyr Asn Glu Val Ala Asp Glu Leu Val Ala Glu Phe Ala
323             115                 120                 125
326 Asp Pro Asn Asn Asn Phe Ala Ser Pro Asp Pro Asp Asn Pro Asn Thr
327         130                 135                 140
330 Pro Gln Phe Asp Glu Lys Asn Ile Arg Arg Arg Val Tyr Asp Ala Leu
331 145                 150                 155                 160
334 Asn Val Leu Met Ala Met Asp Ile Ile Ser Lys Asp Lys Lys Glu Ile
335                 165                 170                 175
338 Gln Trp Lys Gly Leu Pro Arg Thr Ser Met Ser Asp Val Glu Glu Leu
339             180                 185                 190
342 Lys Thr Glu Ile Ile Gly Leu Lys Gly Arg Ile Asp Lys Lys Asn Ala
343             195                 200                 205
346 Tyr Leu Gln Glu Leu Glu Asp Gln Phe Val Gly Leu Gln Asn Leu Ala
347     210                 215                 220
350 Gln Arg Asn Glu Gln Leu Tyr Gly Ser Gly Asn Ala Pro Ser Gly Gly
351 225                 230                 235                 240
354 Val Ala Leu Pro Phe Ile Leu Val Gln Thr Arg Pro His Ala Thr Val
355                 245                 250                 255
358 Glu Val Glu Ile Ser Glu Asp Met Gln Leu Val His Phe Asp Phe Asn
359             260                 265                 270
362 Ser Thr Pro Phe Glu Leu His Asp Asp Ser Phe Val Leu Lys Ala Leu
363         275                 280                 285
366 Gly Phe Ser Gly Lys Glu Pro Asp Asp Thr Gln Ala Trp Val Gly Asn
367     290                 295                 300
370 Gly Gly Glu Cys Ser Thr Thr Pro Ile Tyr His Gln Ser Pro Gln Val
371 305                 310                 315                 320
374 Ala Arg Pro Asn Gly Val Arg Leu Pro Thr Ser Pro Pro Ile Pro Gly
375                 325                 330                 335
378 Ile Leu Lys Gly Arg Val Lys His Glu His
```

<210> 59
<211> 726
<212> DNA
<213> Oryza sativa
<220>
<223>
<220>
<221> CDS
<222> (1)..(726)

INVALID RESPONSE MANDATORY <220> <223> "PLEASE EXPLAIN LOCATION OF XAA" SEE ITEM # 9 ERROR SUMMARY SHEET.

<400> 59

```
atg ggg agg ggg aag ata gtg ata agg agg ata gac aac tcg acg agc    48
Met Gly Arg Gly Lys Ile Val Ile Arg Arg Ile Asp Asn Ser Thr Ser
1               5                   10                  15

agg cag gtg acg ttc tcg aag cgt cgg aac ggg ctt ctg aag aag gcg    96
Arg Gln Val Thr Phe Ser Lys Arg Arg Asn Gly Leu Leu Lys Lys Ala
                20                  25                  30

aag gag cta tcc atc ctc tgc gat gcg gag gtc ggc ctt gtc gtc ttc    144
Lys Glu Leu Ser Ile Leu Cys Asp Ala Glu Val Gly Leu Val Val Phe
            35                  40                  45

tcc agc acc ggc aas ctc tat gag ttc tcc agc acc aac atg aaa act    192
Ser Ser Thr Gly Xaa Leu Tyr Glu Phe Ser Ser Thr Asn Met Lys Thr
        50                  55                  60
```

... of error shown exist the ... ... Listing. Please check sub... ... sequences for similar errors.

RAW SEQUENCE LISTING ERROR SUMMARY   DATE: 05/12/2005
PATENT APPLICATION: US/10/533,232   TIME: 08:24:05

Input Set : D:\1392-10-19 PCT.ST25.txt
Output Set: N:\CRF4\05122005\J533232.raw

Please Note:
Use of n and/or Xaa have been detected in the Sequence Listing. Please review the
Sequence Listing to ensure that a corresponding explanation is presented in the <220>
to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:5; N Pos. 702
Seq#:5; Xaa Pos. 234
Seq#:6; Xaa Pos. 234
Seq#:59; Xaa Pos. 53
Seq#:60; Xaa Pos. 53
Seq#:79; Xaa Pos. 71
Seq#:80; Xaa Pos. 71
Seq#:111; Xaa Pos. 23,56,57,104,126
Seq#:112; Xaa Pos. 23,56,57,104,126
Seq#:121; Xaa Pos. 64
Seq#:122; Xaa Pos. 64
Seq#:137; Xaa Pos. 34
Seq#:138; Xaa Pos. 34
Seq#:151; Xaa Pos. 956,961,1086
Seq#:152; Xaa Pos. 956,961,1086
Seq#:161; Xaa Pos. 264
Seq#:162; Xaa Pos. 264
Seq#:293; Xaa Pos. 226
Seq#:294; Xaa Pos. 226
Seq#:303; Xaa Pos. 2,6
Seq#:304; Xaa Pos. 2,6

Invalid <213> Response:
Use of "Artificial" only as "<213> Organism" response is incomplete,
per 1.823(b) of New Sequence Rules. Valid response is Artificial Sequence.

Seq#:347

VERIFICATION SUMMARY   DATE: 05/12/2005
PATENT APPLICATION: US/10/533,232   TIME: 08:24:05

Input Set : D:\1392-10-19 PCT.ST25.txt
Output Set: N:\CRF4\05122005\J533232.raw

L:9 M:270 C: Current Application Number differs, Replaced Current Application No
L:9 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:454 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 after pos.:672
M:341 Repeated in SeqNo=5
L:623 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:224
L:5577 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ ID#:59
L:5577 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:59 after pos.:192
L:5653 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:60 after pos.:48
L:7834 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ ID#:79
L:7834 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:79 after pos.:240
L:7990 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:80 after pos.:64
L:11109 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ ID#:111
L:11109 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:111 after pos.:96
M:341 Repeated in SeqNo=111
L:11285 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:112 after pos.:16
M:341 Repeated in SeqNo=112
L:12215 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ ID#:121
L:12215 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:121 after pos.:192
L:12307 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:122 after pos.:48
L:13746 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ ID#:137
L:13746 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:137 after pos.:144
L:13994 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:138 after pos.:32
L:16632 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ ID#:151
L:16632 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:151 after pos.:2880
M:341 Repeated in SeqNo=151
L:16970 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:152 after pos.:944
M:341 Repeated in SeqNo=152
L:17914 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ ID#:161
L:17914 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:161 after pos.:816
L:18026 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:162 after pos.:256
L:31473 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ ID#:293
L:31473 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:293 after pos.:720
L:31553 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:294 after pos.:224
L:32309 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ ID#:303
L:32309 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:303 after pos.:48
L:32606 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:304 after pos.:0